Prescription Cholesterol Medications Explained

They lower LDL far more than lifestyle changes alone, and in trials they reduce heart attacks, strokes and cardiovascular death. In the CTT meta-analysis of 26 trials, every 39 mg/dL drop in LDL-C cut major cardiovascular events by about 22%.

Diet and exercise still help cholesterol, fitness and blood pressure. For people with a genetic cause, existing plaque, or LDL that stays high despite a healthy lifestyle, lifestyle changes alone often fall short.

Statins block an enzyme in the liver that makes cholesterol. Atorvastatin, rosuvastatin, simvastatin and pravastatin are all low-cost generics. In atorvastatin's prescribing trials, 40 mg lowered LDL-C by 50% and 80 mg by 60%.

Muscle aches are the most common complaint. If they happen, options include a lower dose, a different statin, or adding non-statin therapy.

Ezetimibe is an inexpensive generic that blocks cholesterol absorption in the intestine. It lowers LDL by about 18% alone. Added to an ongoing statin, it lowered LDL-C by a further 25%, versus 4% for continuing the statin alone. In IMPROVE-IT, adding it to a statin after a heart attack or unstable angina modestly lowered cardiovascular events.

Bempedoic acid (Nexletol) works one step upstream of statins, and the liver activates it more than muscle does. It lowered LDL by about 18% more than placebo on top of a statin in CLEAR Harmony. In CLEAR Outcomes, about 14,000 people who could not take statins had 13% fewer major cardiovascular events. It also comes combined with ezetimibe (Nexlizet).

Lipfendra, approved in July 2026, is the first oral PCSK9 inhibitor.

PCSK9 inhibitors lower LDL-C by roughly another 50 to 60% on top of a statin. Repatha and Praluent are injectable antibodies given every two to four weeks. Lerochol is a monthly self-injection (approved December 2025, launched May 2026). In FOURIER, adding evolocumab to a statin lowered LDL-C by 59% and cut heart attacks, strokes and related events by 15%.

In the GLAGOV trial, 64% of people on evolocumab had plaque regression in the coronary arteries, compared with 47% on placebo.

Inclisiran (Leqvio) is an siRNA shot that a healthcare professional gives twice a year after the first two doses. It lowered LDL by about 50% in ORION-10 and ORION-11. Its outcomes trials have not reported yet.

Icosapent ethyl (Vascepa) is a purified omega-3 fatty acid for people with high triglycerides despite a statin. In REDUCE-IT, 8,179 such patients had a 25% lower risk of major cardiovascular events than with placebo, over a median of 4.9 years.

Treatment usually steps up: a statin at the highest dose you tolerate, then non-statin medicines until LDL and ApoB reach goal. The 2026 ACC/AHA multisociety guideline says adding ezetimibe and/or a PCSK9 inhibitor when LDL stays above goal "should be implemented without delay." It sets an LDL-C goal under 70 mg/dL for people with cardiovascular disease and under 55 mg/dL for those at very high risk.

Bempedoic acid or inclisiran fit especially when statins are not tolerated, and icosapent ethyl fits when triglycerides stay high. Ask your clinician which combination fits you.